ECSP066349A - Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales - Google Patents

Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales

Info

Publication number
ECSP066349A
ECSP066349A EC2006006349A ECSP066349A ECSP066349A EC SP066349 A ECSP066349 A EC SP066349A EC 2006006349 A EC2006006349 A EC 2006006349A EC SP066349 A ECSP066349 A EC SP066349A EC SP066349 A ECSP066349 A EC SP066349A
Authority
EC
Ecuador
Prior art keywords
novedosos
antitumor agents
transfer inhibitors
protein transfer
compounds
Prior art date
Application number
EC2006006349A
Other languages
English (en)
Inventor
Viyyoor M Girijavallabhn
F George Njoroge
Alan B Cooper
Dinanath F Rane
Ronald J Doll
James J-S Wang
Jagdish A Desai
Hugh Y Zhu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34138747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066349(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP066349A publication Critical patent/ECSP066349A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se dan a conocer compuestos tricíclicos novedosos de la fórmulay sales y solvatos farmacéuticamente aceptables de los mismos. Los compuestos son útiles para la inhibición de transferasa de proteína de farnesilo. También se dan a conocer composiciones farmacéuticas que comprenden los compuestos de la fórmula (I). También se dan a conocer usos de los compuestos de la fórmula I para la fabricación de un medicamento para el tratamiento de cáncer.
EC2006006349A 2003-08-07 2006-02-06 Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales ECSP066349A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49326903P 2003-08-07 2003-08-07
US49850903P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
ECSP066349A true ECSP066349A (es) 2006-08-30

Family

ID=34138747

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006349A ECSP066349A (es) 2003-08-07 2006-02-06 Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales

Country Status (19)

Country Link
US (1) US7557107B2 (es)
EP (1) EP1660477B1 (es)
JP (1) JP2007501791A (es)
KR (1) KR20060057599A (es)
AR (1) AR045447A1 (es)
AT (1) ATE417041T1 (es)
AU (1) AU2004263493A1 (es)
BR (1) BRPI0413384A (es)
CA (1) CA2535210A1 (es)
DE (1) DE602004018332D1 (es)
EC (1) ECSP066349A (es)
ES (1) ES2317047T3 (es)
HK (1) HK1087122A1 (es)
IL (1) IL173514A0 (es)
MX (1) MXPA06001483A (es)
PE (1) PE20050336A1 (es)
RU (1) RU2006106768A (es)
TW (1) TW200510384A (es)
WO (1) WO2005014577A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
AU2003272767A1 (en) * 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
CA2591705A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
CN101198314A (zh) * 2005-04-12 2008-06-11 伊兰制药国际有限公司 纳米微粒喹唑啉衍生物制剂
CN101222926B (zh) * 2005-04-15 2013-07-17 默沙东公司 用于治疗或预防癌症的方法和组合物
US20070213340A1 (en) * 2006-01-19 2007-09-13 Kelly Joseph M Farnesyl protein transferase inhibitors
EP1854465A1 (en) 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
EP2087113A2 (en) * 2006-10-11 2009-08-12 Fusion Antibodies Limited Combination therapy
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
IL125062A (en) 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
WO2001064199A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
US20030229099A1 (en) * 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CN1849122A (zh) 2001-12-03 2006-10-18 先灵公司 Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途
AU2003272767A1 (en) * 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
CA2591705A1 (en) 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents

Also Published As

Publication number Publication date
MXPA06001483A (es) 2006-05-15
US20050059672A1 (en) 2005-03-17
DE602004018332D1 (de) 2009-01-22
WO2005014577A1 (en) 2005-02-17
EP1660477A1 (en) 2006-05-31
WO2005014577A9 (en) 2006-03-23
EP1660477B1 (en) 2008-12-10
HK1087122A1 (en) 2006-10-06
ATE417041T1 (de) 2008-12-15
PE20050336A1 (es) 2005-05-30
JP2007501791A (ja) 2007-02-01
US7557107B2 (en) 2009-07-07
RU2006106768A (ru) 2007-09-20
TW200510384A (en) 2005-03-16
ES2317047T3 (es) 2009-04-16
AU2004263493A1 (en) 2005-02-17
KR20060057599A (ko) 2006-05-26
IL173514A0 (en) 2006-07-05
AR045447A1 (es) 2005-10-26
CA2535210A1 (en) 2005-02-17
BRPI0413384A (pt) 2006-10-17

Similar Documents

Publication Publication Date Title
ECSP066349A (es) Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
UY27882A1 (es) Compuestos quimicos
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
PA8547701A1 (es) Nucleosidos 4 substituidos.
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
UY28691A1 (es) Derivados de difenilazetidona
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY28695A1 (es) Derivados de difenilazetidona
AR063097A1 (es) Pirazolopirimidinas[1,5-a] inhibidoras de quinasas dependientes de ciclina(cdk), composiciones farmaceuticas que las contienen y usos en el tratamiento de enfermedades proliferativas
AR047922A1 (es) Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
HN2003000272A (es) Formulaciones que comprenden un compuesto de indolinona
BR0308071A (pt) Inibidores da protéina farnesil transferase como agentes antitumores